Association of financial status and the quality of life in Chinese women with recurrent ovarian cancer

Zhuyan Shao¹, Tao Zhu¹*, Ping Zhang¹, Qiang Wen¹, Dan Li¹ and Shihua Wang²

Abstract

Background: Very few studies have examined the association between financial status and the quality of life (QOL) of patients with specific cancers. Ovarian cancer survivors frequently suffer repeat recurrence and subsequent treatment and, as a result, a significant added financial burden. Financial burdens disproportionally affect patients of low income. This study examines the association between financial status, based upon family income and expenses, and QOL in Chinese women with recurrent ovarian cancer.

Methods: We assessed baseline and follow-up (3-month) QOL of Chinese women with recurrent ovarian cancer using the European Organization for Research and Treatment of Cancer 30-Item Core Quality of Life Questionnaire (EORTC QLQ-C30), and the Quality of Life Ovarian Cancer 28 Questionnaire (QLQ-OV28). Financial status was stratified based upon self-reported disposable income. Linear or logistic regression models were applied to determine the relationship between QOL in each financial status category, and key demographic and clinical factors.

Results: Among all 473 ovarian cancer patients, 123 of them met enrollment criteria were recruited to this study and completed baseline questionnaires; 95 of these patients completed the 3-month follow-up questionnaires. Our results showed that low financial status was significantly associated with worse QOL on all functioning domains and several symptom domains. QOL deteriorated during the follow-up. A significantly greater number of patients with low financial status experienced deteriorating QOL in several domains. Occupation and insurance type, two factors related to financial status, were significantly associated with QOL as well, but to a lesser extent. Education, recurrence interval, age and BMI were also significantly related to certain domains of QOL.

Conclusions: Financial status is associated with QOL of Chinese women with recurrent ovarian cancer. These patients showed worsening QOL during active chemotherapy. Lower financial status is associated with a higher risk of deteriorating QOL in several domains.

Keywords: recurrent ovarian cancer, quality of life, financial status

Background

Advances in treatments for ovarian cancer over the past 40 years have resulted in an increase in the 5-year survival rate from 21% to 46% among patients [1]. Unfortunately, the majority of ovarian cancer survivors will experience repeated recurrence and undergo multiple chemotherapies at varied intervals. Recurrent ovarian cancer patients must tolerate the fear of recurrence and of treatments and related side effects, all of which significantly impact quality of life (QOL). Improved QOL has been shown to increase survival rates and prolong survival time among ovarian cancer patients [2]. Studies in this field will aid in development of interventions and palliative efforts to maintain and improve QOL and thereby prolong survival time for ovarian cancer patients [3].

Indisputable realities for recurrent ovarian cancer patients are the huge costs for treatment of recurrent disease and possible loss of income due to the disease. Indeed, increased financial burdens for cancer patients has been extensively reported [4–9]. Three recent cross-
sectional studies using data from large cohorts demonstrated the impacts of financial burdens on QOL of cancer patients [10–12]. These studies provide strong evidence of the impact of financial burden on the QOL and mental health of cancer patients.

Financial burdens disproportionately affect patients of low income. It is more appropriate to define financial burden in terms of both family income and expenses. Financial burden is influenced by local living standards. Different definitions of financial burden have been previously reported, such as length of financial reserve [10], patient charges [13], economic events [4], self-reported financial problems [12] and other definitions[11]. The lack of a uniform definition of financial burden highlights the importance of studying the impact of financial burden on QOL in different ethnic populations with different living conditions.

Few studies have examined the association of financial burden on the QOL of patients with specific cancers [4]. Our study aimed to assess the association of financial status and QOL among Chinese women actively undergoing chemotherapy for recurrent ovarian cancer.

**Methods**

**Patients**

This study was approved by the Ethics Committee of Zhejiang Cancer Hospital (IRB2012–21-1). All patients signed informed consent forms prior to completing the surveys.

A total of 473 ovarian cancer patients underwent either cytoreductive surgery or chemotherapy at the Department of Gynecologic Oncology of Zhejiang Cancer Hospital from June, 2012 to February, 2014. Diagnosis of recurrent ovarian cancer were based upon the criteria of the Gynecological Cancer Intergroup (GCIG): (1) A 20% increase in the sum of tumor diameters (RECIST 1.1 definition) and CA 125 ≥ 2× the upper limit of response range (ULRR) documented on two occasions (repeated measurement of CA 125 not less than 1 week after the first elevated CA 125 level); (2) Any new lesions (measurable or non-measurable); (3) unequivocal increase in non-target disease; and (4) CA 125 ≥ 2× the nadir value on two occasions [14]. A total of 123 eligible patients with newly or previously diagnosed recurrent ovarian cancer who were actively undergoing chemotherapy were enrolled in this study.

Demographic and clinical data of the enrolled participants, including age, marital status, education, occupation, type of insurance, financial status, and number of recurrences and intervals between recurrences, were collected by reviewing medical records and interviewing patients. The recently adopted “universal health care” policy allows the government to provide medical insurance to all Chinese citizens [15]. However, patients with urban medical insurance have a much lower out-of-pocket cost than those with rural medical insurance. Financial status was based on self-reported annual family income minus expenses (Disposable income). Patients were divided into three financial strata based on this information: low (less than $6000); fair ($6000 to $25,000); and good (over $25,000).

**QOL evaluation**

Two commonly-used questionnaires were employed to estimate the QOL of study participants: the simplified Chinese version (3.0) of the European Organization for Research and Treatment [EORTC] 30-Item Core Quality of Life Questionnaire (QLQ-C30), and the simplified Chinese version of the QLQ-OV28 questionnaire which is specific to ovarian cancer. Previous studies have shown that both questionnaires yield outcomes that demonstrate reliability, validity, feasibility, and reactivity [16]. Both the QLQ C30 and the QLQ-OV28 questionnaire were administered at a baseline time point and again after 3–4 cycles of chemotherapy (at roughly 3 months). Scoring and scaling of questionnaires were conducted in strict accordance with the steps stipulated by the EORTC QOL group. Higher scores of functioning and global health in the QLQ-C30, and sexual functioning in the QLQ-OV28, indicated higher QOL. Higher individual symptom scores represented more severe symptoms [17, 18].

**Statistical analysis**

Statistical analysis was performed using SAS (Cary, NC) version 9.3 software. Descriptive statistics were applied to demographic and clinical data, and QOL outcomes at baseline and follow-up. The difference between baseline and follow-up QOL outcomes was examined by paired T-test. The relationship between demographic and clinical factors and financial status and QOL outcomes were evaluated using univariate or multivariate linear regression models. Logistic regression models were applied to assess whether financial status could predict the risk of deteriorating QOL over time. Statistically significant results were indicated by P-values <0.05.

**Results**

**Demographic and clinical information**

Detailed information concerning age, marital status, education, occupation, financial status, insurance type, recurrences times and intervals, and sites of recurrence is shown in Table 1, along with stratification by financial status. Our results showed that while patients in different financial strata had similar age, marital status, circumstances of recurrence and chemotherapy regimens, the group of patients with higher financial status was enriched for those with higher education, urban
Table 1  Demographic and clinical data based on financial status

| Variables                         | Overall (n = 123) | Financial status                  | P     |
|-----------------------------------|-------------------|-----------------------------------|-------|
|                                   |                   | Low (n = 20)                      | Fair (n = 47) | Good (n = 56) |
| Age                               | 53.4 ± 9.3        | 51.5 ± 10.1                       | 53.7 ± 9.8 | 53.9 ± 8.6 | 0.585 |
| BMI                               | 21.1 ± 1.3        | 21.0 ± 1.5                       | 21.2 ± 1.4 | 21.0 ± 1.1 | 0.737 |
| Marital status                    |                   |                                  |       |     |
| Married                           | 113 (91.9%)       | 17 (85.0%)                        | 42 (89.4%) | 54 (96.4%) | 0.438 |
| Single superscript a              | 10 (8.1%)         | 3 (15%)                           | 5 (10.6%) | 2 (3.6%)   |
| Education                         |                   |                                  |       |     |
| Junior high school or lower       | 86 (78.0%)        | 19 (95.0%)                        | 39 (83.0%) | 38 (67.9%) | 0.025 |
| Senior high school or above       | 27 (22.0%)        | 1 (5.0%)                          | 8 (17.0%) | 18 (32.1%) |
| Occupation                        |                   |                                  |       |     |
| Farmer or housewife               | 46 (37.4%)        | 17 (85.0%)                        | 22 (46.8%) | 7 (12.5%)  | <0.0001 |
| Factory worker                    | 15 (12.2%)        | 3 (15.0%)                         | 6 (12.8%) | 6 (10.7%)  |
| Enterprise employee               | 20 (16.3%)        | 3 (6.4%)                          | 17 (30.4%) |
| Self-employed                     | 7 (5.7%)          | 2 (4.2%)                          | 5 (8.9%)  |
| Retired                           | 35 (28.5%)        | 14 (29.8%)                        | 21 (37.5%) |
| Insurance type                    |                   |                                  |       |     |
| Urban medical insurance           | 75 (61.0%)        | 3 (15.0%)                         | 19 (40.4%) | 53 (94.6%) | <0.0001 |
| Rural medical insurance           | 48 (39.0%)        | 17 (85.0%)                        | 28 (59.6%) | 3 (5.4%)   |
| Surgery                           | 23 (18.7%)        | 4 (20.0%)                         | 9 (19.1%) | 10 (17.9%) |
| Number of recurrences             |                   |                                  |       |     |
| 1                                 | 80 (65.0%)        | 15 (75.0%)                        | 31 (66.0%) | 34 (60.7%) | 0.509 |
| 2–10                              | 43 (35.0%)        | 5 (25.0%)                         | 16 (34.0%) | 22 (39.3%) |
| Recurrence interval               |                   |                                  |       |     |
| ≤ 12 months                       | 74 (60.2%)        | 12 (60.0%)                        | 27 (57.4%) | 35 (62.5%) | 0.451 |
| 12–90 months                      | 49 (39.8%)        | 8 (40.0%)                         | 20 (42.6%) | 21 (37.5%) |
| Site of recurrence                |                   |                                  |       |     |
| Pelvic                            | 27 (22.0%)        | 6 (30.0%)                         | 9 (19.1%) | 12 (21.4%) | 0.380 |
| Abdominal                         | 41 (33.3%)        | 3 (15.0%)                         | 19 (40.4%) | 19 (33.9%) |
| Distant metastasis                | 55 (44.7)         | 11 (55.0%)                        | 19 (40.4%) | 25 (44.7%) |
| Chemotherapy                      |                   |                                  |       |     |
| Paclitaxel plus Carboplatin       | 36 (29.3%)        | 6 (30.0%)                         | 14 (29.8%) | 16 (28.6%) | 0.969 |
| Docetaxel plus Carboplatin        | 34 (27.6%)        | 5 (25.0%)                         | 11 (23.4%) | 18 (32.1%) |
| Gemcitabine plus Cisplatin        | 33 (26.8%)        | 5 (25.0%)                         | 14 (29.8%) | 14 (25.0%) |
| Others superscript b              | 20 (16.3%)        | 4 (20.0%)                         | 8 (17.0%) | 8 (14.3%)  |

* superscript a including unmarried, divorced or widowed

* superscript b chemotherapies with FOLFOX; or Cisplatin plus Topotecan, or Cisplatin plus Liposomal doxorubicin

medical insurance, self-employed status, and employees and retirees from enterprise.

**Financial status and QOL**

All 123 patients finished both QLQ C30 and QLQ-OV28 questionnaires at the baseline. QOL scores of patients at different financial strata are shown in Table 2. At the baseline, the global health score (57.0 ± 18.1) in the QLQ-C30 was very low. The lowest score (64.2 ± 25.8) was in the area of social functioning. Financial difficulty (56.5 ± 21.9) was the most severe among symptom domains. The QLQ-OV28 sexuality score was extremely low. Of the 123 patients, 106 (86.2%) reported a complete loss of interest in sex and the remaining 17 (13.8%) reported a low interest in sex. A total of 112 (91.1%) patients reported a lack of sexual activity. Only 11 patients reported that they were sexually active, but all of them indicated that they experience little sexual enjoyment. Eight of them reported no vaginal dryness, two reported little vaginal dryness, and one reported obvious vaginal dryness.
Table 2  Relationship between financial status and QOL

| Outcomes      | Overall (n = 123) | Financial status | Coefficient (95%CI) | P     | Coefficient (95%CI) | P     |
|---------------|-------------------|------------------|---------------------|-------|---------------------|-------|
|               |                   | Low (n = 20)     | Fair (n = 47)       | Good (n = 56) |                   |       |
| QLQ-C30       |                   |                  |                     |        |                     |       |
| Physical functioning | 80.0 ± 18.9        | 74.3 ± 16.4      | 75.7 ± 27.2         | 85.7 ± 20.7 | 4.4 (0.2 ~ 8.6) | 0.038 |
| Role functioning     | 78.5 ± 26.3        | 71.7 ± 33.4      | 72.7 ± 27.2         | 85.7 ± 20.7 | 8.3 (2.0 ~ 14.6) | 0.010 |
| Cognitive functioning | 78.6 ± 17.5        | 72.5 ± 22.5      | 75.5 ± 19.0         | 83.3 ± 12.7 | 59 (1.7 ~ 10.1) | 0.006 |
| Emotional functioning | 72.4 ± 19.2        | 64.6 ± 21.3      | 68.4 ± 18.9         | 78.4 ± 17.0 | 76 (3.1 ~ 12.1) | 0.001 |
| Social functioning     | 64.2 ± 25.8        | 50.8 ± 29.4      | 55.7 ± 22.6         | 76.2 ± 21.8 | 143 (8.5 ~ 20.1) | <0.0001 |
| Global health           | 57.0 ± 18.1        | 57.5 ± 23.7      | 52.7 ± 22.5         | 59.4 ± 20.7 | NS                  |       |
| Financial difficulties | 56.5 ± 21.9        | 93.3 ± 13.7      | 57.4 ± 28.4         | 27.4 ± 25.5 | −324 (−38.5 ~ −26.2) | <0.0001 |
| Fatigue                | 37.2 ± 19.6        | 39.4 ± 22.1      | 40.2 ± 20.7         | 33.9 ± 17.4 | NS                  |       |
| Nausea and vomiting    | 8.5 ± 14.8         | 8.3 ± 13.8       | 9.9 ± 17.3          | 7.4 ± 13.1  | NS                  |       |
| Pain                   | 21.8 ± 25.0        | 28.3 ± 27.1      | 24.1 ± 24.8         | 17.6 ± 24.1 | NS                  |       |
| Dyspnea                | 15.4 ± 21.9        | 16.7 ± 20.3      | 14.2 ± 18.1         | 16.1 ± 25.4 | NS                  |       |
| Insomnia               | 32.2 ± 29.9        | 28.3 ± 27.1      | 34.0 ± 30.7         | 32.1 ± 30.5 | NS                  |       |
| Appetite loss          | 18.7 ± 24.1        | 18.3 ± 27.5      | 18.3 ± 20.6         | 19.0 ± 26.1 | NS                  |       |
| Constipation           | 19.0 ± 30.8        | 28.3 ± 34.7      | 27.7 ± 36.3         | 8.3 ± 19.3  | −120 (−19.2 ~ −4.7) | 0.001 |
| Diarrhea               | 9.5 ± 17.3         | 5.0 ± 12.2       | 9.2 ± 16.6          | 11.3 ± 19.4 | NS                  |       |
| QLQ-OV28               |                   |                  |                     |        |                     |       |
| Body image             | 48.0 ± 24.9        | 60.0 ± 27.8      | 50.4 ± 22.9         | 41.7 ± 24.0 | −40 (−7.9 ~ −0.2) | 0.003 |
| Sexual functioning     | 3.9 ± 9.6          | 6.67 ± 12.6      | 3.5 ± 10.4          | 3.2 ± 7.4  | NS                  |       |
| Attitude toward disease/treatment | 60.5 ± 27.5    | 76.7 ± 23.6      | 66.7 ± 25.1         | 49.6 ± 26.6 | −143 (−20.5 ~ −8.0) | <0.0001 |
| Abdominal symptoms     | 19.7 ± 16.3        | 22.1 ± 20.7      | 23.1 ± 15.7         | 16.1 ± 14.5 | NS                  |       |
| Neurological symptoms  | 28.5 ± 22.5        | 30.6 ± 31.2      | 31.7 ± 22.5         | 25.0 ± 18.6 | NS                  |       |
| Menopausal symptoms    | 15.1 ± 17.5        | 16.7 ± 12.6      | 12.7 ± 14.8         | 14.6 ± 19.3 | NS                  |       |
| Other side-effects      | 15.5 ± 13.1        | 22.3 ± 19.6      | 16.3 ± 12.6         | 13.7 ± 11.8 | −40 (−7.3 ~ −0.6) | 0.020 |

Higher scores of functioning and global health in the QLQ-C30, and sexual functioning in the QLQ-OV28, indicate higher QOL. A higher score of individual symptoms represents increased symptom severity. 

Univariate linear regression analysis. CI confidence interval. 

Multivariate analysis controlled for age, marital status, education, occupation, surgery, insurance type, number and interval of recurrence.
Linear regression models were used to establish the correlation between financial status and QOL at the baseline measurement (Table 2). Our results showed that patients with low financial status fared worse with respect to physical functioning \((P = 0.038)\), role functioning \((P = 0.010)\), cognitive functioning \((P = 0.005)\), emotional functioning \((P = 0.006)\) and social functioning \((P < 0.0001)\). They suffered greater financial difficulties \((P = 0.001)\), more severe symptoms of constipation \((P = 0.001)\), poor body image \((P = 0.003)\), poor attitude toward treatment and disease \((P < 0.0001)\), and other chemotherapy side effects \((P = 0.020)\). Most of these associations were maintained or became even more significant after adjusting for age, marriage, education, occupation, surgery, insurance type, and recurrence times and intervals.

There were 95 patients that completed both the baseline and follow-up surveys and changes in QOL outcomes were determined for this group. Our results showed that physical, role functioning and cognitive functioning, as well as the domains of nausea and vomiting, insomnia, appetite loss and other side-effects were deteriorated significantly (Table 3).

We then identified patients with deteriorating QOL whose scores decreased in a functioning domain, global health and sexual functioning; or increased in other symptom domains during follow-up. We applied a logistic regression model to determine whether financial status predicted the risk of deteriorating QOL. Our results showed that patients with low financial status had a significantly higher risk of deteriorating QOL in the domains of physical functioning \((P = 0.001)\), role functioning \((P = 0.0140)\), emotional functioning \((P = 0.021)\), pain \((P = 0.010)\) and financial difficulties \((P = 0.003)\) (Table 4).

### Association of other demographic and clinical factors and QOL

Linear regression analysis showed that patients with urban medical insurance demonstrated significantly increased cognitive functioning \((P = 0.011)\), emotional functioning \((P = 0.001)\), and social functioning \((P = 0.0002)\), less severe symptoms of constipation \((P = 0.011)\), financial difficulties \((P < 0.0001)\), attitude toward disease and treatment \((P = 0.001)\), and abdominal symptoms \((P = 0.030)\). Patients' occupations were classified as self-employed, current or retired enterprise employees with the highest incomes, factory workers with moderate incomes, and farmers and housewives with the lowest incomes. Occupations with higher income were significantly associated with better QOL in the areas of cognitive functioning \((P = 0.040)\), emotional functioning \((P = 0.002)\), global health \((P < 0.0001)\), financial difficulties \((P < 0.0001)\), and attitude toward disease and treatment \((P = 0.044)\). Chemotherapy regimens were significantly associated with cognitive functioning \((P = 0.031)\), nausea and vomiting \((P = 0.045)\), and attitude toward disease and treatment \((P = 0.031)\). Longer recurrence intervals were significantly associated with fewer financial difficulties \((P = 0.005)\). Increased age was significantly associated with poor attitude toward disease and treatment \((P = 0.014)\) and sexual functioning \((P = 0.026)\). Patients with BMI of 20 or more suffered less severe symptoms of nausea and vomiting compared to those with BMI less than 20 \((P = 0.003)\). Our study showed that marital status, and number and sites of recurrences were not associated with QOL of recurrent ovarian cancer patients. Only factors that were significantly correlated with QOL domains are shown in Table 5.

### Discussion

With prolonged survival, many ovarian cancer patients experience recurrence, subsequent treatments and related heavy financial burdens. Previous studies have focused on the QOL of newly diagnosed ovarian cancer patients [19–23]. To the best of our knowledge, this study

### Table 3: Scores of QOL in paired 95 patients at two time points

| Outcomes                      | Baseline       | Follow-up      | *P* values |
|-------------------------------|----------------|----------------|------------|
| QLQ-C30                       |                |                |            |
| Physical functioning          | 77.2 ± 17.2    | 74.1 ± 14.8    | 0.039      |
| Role functioning              | 75.6 ± 27.5    | 69.6 ± 25.5    | 0.047      |
| Cognitive functioning         | 78.4 ± 18.2    | 70.9 ± 22.0    | 0.002      |
| Emotional functioning         | 73.0 ± 18.0    | 75.3 ± 17.2    | 0.237      |
| Social functioning            | 63.2 ± 27.0    | 58.6 ± 24.5    | 0.132      |
| Global health                 | 54.2 ± 21.7    | 57.0 ± 18.1    | 0.300      |
| Financial difficulties        | 49.5 ± 33.6    | 51.9 ± 32.5    | 0.365      |
| Fatigue                       | 38.4 ± 19.1    | 37.3 ± 17.5    | 0.638      |
| Nausea and vomiting           | 9.1 ± 15.1     | 15.1 ± 18.0    | 0.003      |
| Pain                          | 22.5 ± 24.2    | 20.0 ± 15.1    | 0.367      |
| Dyspnea                       | 15.1 ± 21.6    | 17.5 ± 21.1    | 0.320      |
| Insomnia                      | 34.4 ± 19.1    | 29.4 ± 26.2    | 0.001      |
| Appetite loss                | 18.9 ± 23.1    | 26.3 ± 24.3    | 0.033      |
| Constipation                  | 200.0 ± 31.7   | 204.0 ± 27.6   | 0.912      |
| Diarrhea                      | 7.4 ± 13.9     | 6.3 ± 14.0     | 0.580      |
| QLQ-OV28                      |                |                |            |
| Body image                    | 48.4 ± 24.6    | 45.6 ± 28.4    | 0.386      |
| Sexual functioning            | 3.5 ± 8.7      | 3.0 ± 9.7      | 0.567      |
| Attitude toward disease/treatment | 60.4 ± 26.6   | 55.9 ± 27.2    | 0.110      |
| Abdominal symptoms            | 19.6 ± 16.1    | 17.7 ± 14.2    | 0.287      |
| Neurological symptoms         | 30.2 ± 22.0    | 31.2 ± 21.9    | 0.681      |
| Menopausal symptoms           | 15.1 ± 17.5    | 17.9 ± 17.0    | 0.138      |
| Other side-effects            | 15.5 ± 13.1    | 18.8 ± 13.3    | 0.029      |
represents the first investigation of the association of financial status and QOL of recurrent ovarian cancer patients.

One of the most significant findings is the strong association of financial status and QOL of recurrent ovarian cancer patients. Based on QOL scores, our data showed that the most severe symptom, indicated by the highest score, was financial difficulties. Low financial status was associated with poor QOL in all functioning domains, increased financial difficulties, and increased symptom severity. In addition, patients with low financial status experienced a higher risk of deteriorating QOL in several domains including physical, role and emotional functioning, financial difficulties and pain. In agreement with our findings, the association of financial burden and QOL has been reported in general cancer populations [10–12].

Our study revealed that both occupation and type of insurance were significantly associated with QOL. Patients with occupations of higher income were associated with better QOL in some domains. Patients with rural medical insurance which provides less coverage of medical cost and imposes more out-of-pocket expenses had lower QOL. These findings indicate that the financial status of recurrent ovarian cancer patients is associated with QOL.

Ovarian cancer recurrence creates many symptoms, such as intestinal obstruction, pain, hydrothorax, and ascites. Patients also suffer the complications caused by surgery and adverse reactions to chemotherapies. Patients with recurrent cancer tended to be more pessimistic regarding their prognoses and financial burdens than patients who were newly diagnosed. All recurrent ovarian cancer patients in our study were actively undergoing chemotherapy. Our data revealed that their QOL deteriorated in the domains of physical, role and cognitive functioning, nausea and vomiting, insomnia, appetite loss, insomnia and other side effects. This finding underscores the importance of longitudinal or dynamic assessment of QOL during the trajectory of disease [24]. Similarly, previous studies reported that ovarian cancer patients were shown to have worse QOL compared to healthy women [25], and QOL was even worse in patients with ovarian cancer at advanced stages [26].

Table 4 Relationship between financial status and deteriorating domains of QOL during chemotherapy

| Outcomes              | Financial status          | Coefficient (95% CI) | P      |
|-----------------------|---------------------------|----------------------|--------|
|                       | Low (n = 11)              | Fair (n = 37)        | Good (n = 47) |        |
| Physical functioning  |                           |                      |        |
|                       | 6 (54.5%)                 | 12 (32.4%)           | 6 (12.8%) | −1.2 (−2.0 ~ −0.5) | 0.001 |
| Role functioning      |                           |                      |        |
|                       | 3 (27.3%)                 | 14 (37.8%)           | 5 (10.6%) | −0.9 (−0.2 ~ 1.6)  | 0.014 |
| Emotional functioning |                           |                      |        |
|                       | 6 (54.5%)                 | 18 (48.6%)           | 13 (27.7%) | −0.7 (−1.4 ~ −0.1) | 0.021 |
| Pain                  |                           |                      |        |
|                       | 3 (27.3%)                 | 5 (13.5%)            | 8 (17.0%) | −0.8 (−1.5 ~ −0.2) | 0.010 |
| Financial difficulties |                           |                      |        |
|                       | 4 (36.4)                  | 11 (29.7%)           | 7 (14.9%) | −0.8 (−1.4 ~ −0.1) | 0.003 |

Table 5 Demographic and clinical factors significantly associated with QOL

| Demographic and clinical factors | Occupationa | Insurancetypeb | Educationc | Chemotherapy | Recurrence intervald | Age | BMI |
|---------------------------------|-------------|----------------|------------|---------------|----------------------|-----|-----|
| QLQ-C30                         |             |                |            |               |                      |     |     |
| Cognitive functioning           | 2.1 (0.040)a| −8.2 (0.011)   | 3.2 (0.031) |               |                      |     |     |
| Emotional functioning           | 3.4 (0.002) | −12.2 (0.001) |            |               |                      |     |     |
| Social functioning              | −17.1 (0.0002) |            |            |               |                      |     |     |
| Financial difficulties          | −9.3 (<0.0001) | −6.7 (0.023) | −0.8 (0.005) |               |                      |     |     |
| Constipation                    | 14.4 (0.011) |            |            |               |                      |     |     |
| Nausea and vomiting             | −2.5 (0.045) |            |            |               |                      |     | −1.7 (0.003) |
| QLQ-OV28                        |             |                |            |               |                      |     |     |
| Attitude toward disease         | −3.2 (0.044) | 16.1 (0.001)  | 5.0 (0.031) | −0.7 (0.014)   |                      |     |     |
| Sexual functioning              | −1.3 (0.016) | 3.8 (0.031)   |            | −0.2 (0.026)   |                      |     |     |
| Abdominal symptoms              | 6.5 (0.030)  |            |            |               |                      |     |     |
| Menopausal symptoms             | −0.3 (0.019) |            |            |               |                      |     |     |

*aFarmer or housewife, Factory worker, Enterprise employee, Self-employed, Retired
bUrban and rural medical insurance
cJunior high school or lower and senior high school or above
d≤12 months and 12–90 months
eCoefficient (P value)
Our study revealed that age, BMI, education, chemotherapcy regimens and recurrence intervals were associated with some domains of QOL of recurrent ovarian cancer patients. Smits et al. [20, 21] reported that obese ovarian cancer patients had lower QOL in the domains of global health, physical, cognitive and social functioning, and several symptoms. Sedentary behavior was associated with lower QOL in domains of global health, physical, role, social and sexual functioning. Another study found that physical symptoms had a lower impact on global QOL than psychosocial factors in ovarian cancer patients, whereas demographic and clinical factors, such as age, cancer stage, and histology, did not have a significant impact on QOL [23]. Furthermore, global QOL and five functioning scores were reported to be dependent, in part, on age, marital status, and education in patients with gynecologic cancer [27]. The different factors associated with QOL identified in these studies underscores the importance of studying cancer patients at different stages and from different ethnic backgrounds.

Sexual dysfunction is expected in ovarian cancer patients, mainly due to the menopause caused by oophorectomy in premenopausal women [28]. Decreased hormone levels after oophorectomy result in vaginal dryness and atrophy, urinary incontinence, lower sex drive, and related symptoms. Sexual dysfunction may be also caused by distortion of self-image and fear of physical harm, as well as advanced age, poor physical status, and fatigue [29, 30]. Recurrent ovarian cancer patients and their spouses tend to focus on the cancer recurrence at the expense of sexual needs. Some patients mistakenly believed that an active sex life could lead to recurrence. Based on QLQ-OV28 scores, we found that the vast majority of patients with recurrent ovarian cancer lost sexual interest (86.2%) or had no sexual activity (91.1%). A previous study reported that <10% of early-stage ovarian cancer survivors had an interest in sex or engaged in sexual activity in spite of a comparatively high physical functioning score [31]. These findings indicate that medical intervention may be necessary to promote improvements in sexual function of ovarian cancer survivors following recurrence and subsequent treatments. Psychological counseling and careful hormone replacement therapy may be helpful.

The limitations of this study include those imposed by the non-randomized design and relatively small sample size. All patients were actively undergoing chemotherapy and were recruited from one single cancer hospital. Self-reported surveys were used to characterize financial status. No detailed expense reports were collected from patients. Other QOL related factors, such as disease progression, toxicity, mental health, family and other supports, were not analyzed in this study. Causality could not be established due to the cross sectional nature of the primary analysis. Nonetheless, this study reveals an association between financial status and QOL of Chinese women with recurrent ovarian cancer.

Conclusions
This is the first study to investigate the association between financial status and QOL of recurrent ovarian cancer patients. These patients showed deteriorating QOL during active chemotherapy. Lower financial status is associated with a higher risk of deteriorating QOL in several domains. Our data highlight the need to draw increased attention to the financial burdens of recurrent ovarian cancer patients and the impact of this on their QOL.

Abbreviations
CI: Confidence interval; EORTC QLQ-C30: European Organization for Research and Treatment of Cancer 30-item Core Quality of Life Questionnaire; GCIG: Gynecological Cancer Intergroup; QLQ-OV28: Quality of Life Ovarian Cancer 28 Questionnaire; QOL: Quality of life

Acknowledgements
Not applicable.

Funding
This research is supported by the Foundations of Medicine and Hygiene Science and Technology Planning Project of Zhejiang province, China (Grant No. 2012KYB031).

Availability of data and materials
All relevant data are presented in the paper.

Authors’ contributions
ZS and TZ conceived and designed the study. ZS, TZ, PZ, QN and DL performed surveys and attributed to data collection. ZS, SW and TZ analyzed data and wrote manuscript. All authors read and agreed to submit the manuscript.

Ethics approval and consent to participate
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This study was approved by the Ethics Committee of our Cancer Hospital. All patients signed informed consent forms prior to completing the surveys.

Competing of interest
The authors declare that they have no conflict of interest.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1 Department of Gynecologic Oncology, Zhejiang Cancer Hospital, 1 Banshan East Road, Hangzhou, Zhejiang 310022, China. 2 Department of Cancer Biology, Wake Forest School of Medicine, Winston Salem, NC, USA.

Received: 7 June 2016 Accepted: 27 June 2017
Published online: 17 July 2017

References
1. Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang XS, Bannon F, Ahn JV, Johnson CJ, Bonaventure A, et al. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet. 2015; 385(9972):977–1010.
2. Lutgendorf SK, Slavich GM, Diegoest K, Goodheart M, Bender D, Thaker PH, Penedo F, Zimmerman B, Lucci J 3rd, Mendez L, et al. Non-cancer life
stresses contribute to impaired quality of life in ovarian cancer patients. Gynecol Oncol. 2013;131(3):667–73.

3. Chan KY, Chan ML, Yau TC, Li CW, Cheng HW, Sham MK. Quality of life for Hong Kong Chinese patients with advanced gynecological cancers in the palliative phase of care: a cross-sectional study. J Palliat Care. 2012;28(4):259–66.

4. Menezes K, Azuero A, Hassely L, McNeill P, Pisuj M. Does economic burden influence quality of life in breast cancer survivors? Gynecol Oncol. 2012;124(3):437–43.

5. Yabroff KR, Dowling EC, Guy GP Jr, Banegas MP, Davidoff A, Han X, Virgo KS, McNeil TS, Chavlia N, Blanch-Hartigan D, et al. Financial hardship associated with cancer in the United States: findings from a population-based sample of adult cancer survivors. J Clin Oncol Off J Am Soc Clin Oncol. 2016;34(3):259–67.

6. Zajacova A, Dowd JB, Schoeni RF, Wallace RB. Employment and income losses among cancer survivors: estimates from a national longitudinal survey of American families. Cancer. 2015;121(24):4425–32.

7. Bernard DS, Farr SL, Fang Z. National estimates of out-of-pocket health care expenditure burdens among nonelderly adults with cancer: 2001 to 2008. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29(20):2521–6.

8. Angiolillo R, Capriglione S, Aloisi A, Miranda A, de Cicco NC, Terranova C, Adrower R, Ploiti F. Economic impact among family caregivers of patients with advanced gynecologic cancer. Int J Gynecol Cancer. 2015;25(8):1541–6.

9. Short PF, Moran JR, Punekar R. Medical expenditures of adult cancer survivors aged <65 years in the United States. Cancer. 2011;117(12):2791–800.

10. Latham CS, Clonin A, Tucker-Seeley R, Zafar SY, Ayanian JZ, Schrag D. Association of Financial Strain with Symptom Burden and Quality of Life for patients with lung or colorectal cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2016;34(3):259–67.

11. Kale HP, Carroll NV. Self-reported financial burden of cancer care and its effect on physical and mental health-related quality of life among US cancer survivors. Cancer. 2016;122(8):283–9.

12. Fenn KM, Evans SB, McCorkle R, DiGiovanna MP, Pusztai L, Sanft T, Hofstatter EW, Killelea BK, Knobf MT, Lannin DR, et al. Impact of financial burden on survivors’ quality of life. J Oncol Pract. 2014;10(5):332–4.

13. Lamerato L, Havstad S, Gandhi S, Jones D, Nathanson D. Economic burden associated with breast cancer recurrence: findings from a retrospective analysis of health system data. Cancer. 2006;106(9):1875–82.

14. Rustin GJ, Verghese I, Eisenhauer E, Pujade-Lauraine E, Quinn M, Thigpen T, du Bois A, Kristensen G, Jakobsen A, Sasse S, et al. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the gynecological cancer intergroup. Int J Gynecol Cancer. 2011;21(2):419–23.

15. Yu H. Universal health insurance coverage for 1.3 billion people: what accounts for China’s success? Health policy. 2015;119(1):145–52.

16. Paradowski J, Tomaszewski KA, Berezs K, Tomaszewska JM, Pastemak A, Paradowska D, Szczepny G, Golec EB, Greimel ER, Bottomley A. Validation of the polish version of the EORTC QLQ-C28 module for the assessment of health-related quality of life in women with ovarian cancer. Expert Rev Pharmacoecon Outcomes Res. 2014;14(1):57–63.

17. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, debeer D, Groenveld F, Grolleau G, Hany T, de Haes JC, et al. The European Organization for Research and Treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–76.

18. Greimel E, Bottomley A, Cull A, Waldenstrom AC, Arraras J, Chauveton L, Holzner B, Kujanic K, Leeb Z, D’Haese S, et al. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer. Eur J Cancer. 2003;39(1):1402–8.

19. Paxton RJ, Garcia-Prieto C, Berglund M, Hernandez M, Hajek RA, Handy B, Brown J, Jones LA. A randomized parallel-group dietary study for stages II-IV ovarian cancer survivors. Gynecol Oncol. 2012;124(3):410–6.

20. Smits A, Lopes A, Das N, Bekkers R, Galaal K. Quality of life in ovarian cancer survivors: the influence of obesity. Int J Gynecol Cancer. 2015;25(6):16–21.

21. Smits A, Smits A, Lopes A, Das N, Hughes G, Talata A, Pollard A, Bouwman F, Massuger L, Bekkers R, et al. Body mass index, physical activity and quality of life of ovarian cancer survivors: time to get moving? Gynecol Oncol. 2015;139(1):148–54.

22. Ezendam NP, Pijlman B, Bhugwandass C, Pruitt JF, Mols F, Nos MC, Pijnengorg JM, van de Pol-Franse LV. Chemotherapy-induced peripheral neuropathy and its impact on health-related quality of life among ovarian cancer survivors: results from the population-based PROFILES registry. Gynecol Oncol. 2014;135(3):510–7.

23. Teng FF, Kalloger SE, Brotto L, McAlpine JN. Determinants of quality of life in ovarian cancer survivors: a pilot study. J Obstet Gynaecol Can. 2014;36(8):708–15.

24. Meoner V, Gamber EM, Grahsman A, Giesinger JM, Wensbauer P, Szantay M, Zelmet AG, Spener-Unterweger B, Holzner B. Monitoring physical and psychosocial symptom trajectories in ovarian cancer patients receiving chemotherapy. BMC Cancer. 2012;12:77.

25. Kim SI, Lee Y, Lim MC, Joo J, Park K, Lee DO, Park SY. Quality of life and sexuality comparison between sexually active ovarian cancer survivors and healthy women. J Gynecol Oncol. 2015;26(2):148–54.

26. Ferrell B, Cullinean CA, Erkine V, Melanocon C, Urban GC, Juarez G. Perspectives on the impact of ovarian cancer: women’s views of quality of life. Oncol Nurs Forum. 2005;32(6):1143–9.

27. Goker A, Guvenal T, Yanikkerem E, Turhan A, Koyuncu FM. Quality of life in women with gynecologic cancer in Turkey. Asian Pac J Cancer Prev. 2011;12(11):3121–8.

28. Scanlon M, Blaes A, Geller M, Majhail NS, Lindgren B, Haddad T. Patient satisfaction with physician discussions of treatment impact on fertility, menopause and sexual health among pre-menopausal women with cancer. J Cancer. 2013;2:175–25.

29. Pilger A, Richter R, Fotopoulou C, Beteta C, Klapp C, Sehouli J. Quality of life and sexuality of patients after treatment for gynaecological malignancies: results of a prospective study in 55 patients. Anticancer Res. 2012;32(11):5045–9.

30. Levin AO, Carpenter KM, Fowler JM, Brothers BM, Andersen BL, Maxwell GL. Sexual morbidity associated with poorer psychological adjustment among gynecological cancer survivors. Int J Gynecol Cancer. 2010;20(3):461–70.

31. Matulonis UA, Kornblith A, Lee H, Bryan J, Gibson C, Wells C, Lee J, Sullivan L, Persson R. Long-term adjustment of early-stage ovarian cancer survivors. Int J Gynecol Cancer. 2008;18(6):1183–93.